Advances in treatment of Vogt-Koyanagi-Harada syndrome
10.3980/j.issn.1672-5123.2017.6.18
- VernacularTitle:Vogt-小柳原田综合征的治疗进展
- Author:
Guo, HUANG
;
Pei-Zeng, YANG
- Keywords:
Vogt-Koyanagi-Harada syndrome;
corticosteroids;
immunosuppressive agent;
biological agent
- From:
International Eye Science
2017;17(6):1082-1086
- CountryChina
- Language:Chinese
-
Abstract:
Vogt-Koyanagi-Harada (VKH)syndrome is an autoimmune disease attacking against pigmented cells, resulting in blindness and usually affecting multiple organs including ears, meninges, hair and skin.Correct diagnosis and immediate treatment in the early stage is vital to visual prognosis.Currently, corticosteroids is first-line drug.In addition, VKH patients refractory to corticosteroids can choose other treatment such as immunosuppressive agents and biological agents.
